Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.

In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...

While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized. In an effort to cut ...

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed ...

The trend of fewer companies letting employees go, which began in the fourth quarter of last year, has continued. However, more employees were on the chopping block in Q1 2026 than in Q1 2025, due ...

After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition ...

Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.

Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that President Donald Trump had signed off on his ...

After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. But analysts don’t expect much relief, no matter who ...